Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“5) mg/dL 149 (36) 153 (34) 1 (−18 to 19) LDL cholesterol level 0.”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magnetic resonance and…”
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“001 Fibrosis ≥1-point improvement, n (%) 13 (25) 20 (39) 14 (−6 to 34) 0.”
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 501–600 of 1,001
Bril, F., Pearce, R. W., Collier, T. S., & McPhaul, M. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac565 · Cited by 21
Self-citationHu, Y., Li, H., Zhang, H., Chen, X., Chen, J., Xu, Z., You, H., Dong, R., Peng, Y., Li, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42162-0 · Cited by 25
Cusi, K. J., Budd, J., Johnson, E. L., & Shubrook, J. H. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0014 · Cited by 22
“Six paired-biopsy studies have shown that pioglitazone re-verses steatohepatitis in people with type 2 diabetes and treatment duration of 6 months to 3 years (53,54), as reviewed elsewhere in this article collection (49).”
BackgroundSelf-citationBhadoria, A. S., Kedarisetty, C. K., Bihari, C., Kumar, G., Jindal, A., Bhardwaj, A., Shasthry, V., Vyas, T., Benjamin, J., Sharma, S., et al. (2017) · Liver International · doi:10.1111/liv.13396 · Cited by 20
Tsai, H., Li, T., Huang, C., Huang, S., Liu, R.-S., Yang, Y., Hsieh, Y., Lee, K., Huang, Y., Hou, M., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.03.018 · Cited by 20
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 26
Perakakis, N., Joshi, A., Peradze, N., Stefanakis, K., Li, G., Feigh, M., Veidal, S. S., Rosen, G., Fleming, M., & Mantzoros, C. S. (2020) · Hepatology Communications · doi:10.1002/hep4.1558 · Cited by 18
“, thiazolidinediones) are antidiabetic drugs that have additionally demonstrated beneficial effects against NASH in randomized clinical trials.(4,5) Their mechanism of function is not fully understood, but it seems that they achieve beneficial hepatic effects by improving insulin sensitivity, increasing the concentrat…”
BackgroundManka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 24
Sebastiani, G., Patel, K., Ratziu, V., Feld, J. J., Neuschwander‐Tetri, B. A., Pinzani, M., Petta, S., Berzigotti, A., Metrakos, P. P., Shoukry, N. H., et al. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0030 · Cited by 21
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 25
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Bołdys, A., Bułdak, Ł., Maligłówka, M., Surma, S., & Okopień, B. (2023) · Medicina · doi:10.3390/medicina59101789 · Cited by 25
Barbhuiya, P. A., Sen, S., & Pathak, M. P. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09912-w · Cited by 24
Emerging therapies for MASLD and their impact on plasma lipids
Nguyen, M., Asgharpour, A., Dixon, D. L., Sanyal, A. J., & Mehta, A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100638 · Cited by 21
“In another study, 51 % of patients who received pioglitazone 45 mg daily for 18 months had resolution of MASH and improvement in histologic scores at 18 months compared to 19 % in the placebo group [30].”
BackgroundAQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M
Tardelli, M., Bruschi, F. V., Claudel, T., Moreno‐Viedma, V., Halilbasic, E., Marra, F., Herac, M., Stulnig, T. M., & Trauner, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14557-9 · Cited by 20
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
Wang, L., Wang, H., Wu, J., Ji, C., Wang, Y., Gu, M., Li, M., & Yang, H. W. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1635638 · Cited by 31
Zhao, W., Meng, X., Wu, X., Li, X., Li, X., Zhao, T., Yu, L., & Chen, X.-Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771976 · Cited by 18
Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
Mahtab, M. A., Akbar, S. M. F., Roy, P. P., Rahim, M. A., Yesmin, S. M. S., & Islam, S. B. (2022) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1360 · Cited by 18
Hu, S., Ai, Y., Hu, C., Bawa, F. N. C., & Xu, Y. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101372 · Cited by 23
“52,53 In addition to agonists for specific subtypes, pharmacological double PPAR a / g agonists that activate more than one PPAR, called glitazars, have been developed to improve insulin resistance, dyslipidemia, 54 and fatty liver 55 in rodents.”
Current treatment options for nonalcoholic fatty liver disease
Shetty, A., & Syn, W. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000528 · Cited by 19
Kim, J. M., Kim, S. S., Kim, J. H., Kim, M.-K., Kim, T. N., Lee, S. H., Lee, C. W., Park, J. Y., Kim, E. S., Lee, K. J., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0274 · Cited by 17
Alkhouri, N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708899 · Cited by 18
“Vitamin E and pioglitazone have shown some efficacy against NASH in randomized clinical trials [1,2]; however, both medications have been associated with adverse events limiting their utilization by providers [3].”
BackgroundNon-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062758 · Cited by 25
Liu, A., Huang, M., Xi, Y., Deng, X., & Xu, K. (2025) · Biomedicines · doi:10.3390/biomedicines13061422 · Cited by 17
Daniels, S. J., Leeming, D. J., Detlefsen, S., Bruun, M. F., Hjuler, S. T., Henriksen, K., Hein, P., Karsdal, M. A., Brockbank, S., & Cruwys, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.130 · Cited by 17
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong, G., Dashti, F., & Banini, B. A. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15012 · Cited by 19
Hypogonadism and nonalcoholic fatty liver disease
Papadimitriou, K., Mousiolis, A. C., Mintziori, G., Tarenidou, C., Pοlyzos, S. A., & Goulis, D. G. (2024) · Endocrine · doi:10.1007/s12020-024-03878-1 · Cited by 19
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yang, Y., Zhao, Y., Li, W., Wu, Y., Wang, X., Wang, Y., Liu, T.-M., Ye, T., Xie, Y., Cheng, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112311 · Cited by 17
Non‑alcoholic fatty liver disease: A major challenge in type�2 diabetes mellitus (Review)
Bică, C., Sandu, C., Suceveanu, A., Sarbu, E., Stoica, R. A., Gherghiceanu, F., Bohîlțea, R. E., Ștefan, S., & Stoian, A. P. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8882 · Cited by 22
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes
Bril, F., McPhaul, M. J., Kalavalapalli, S., Lomonaco, R., Barb, D., Gray, M. E., Shiffman, D., Rowland, C. M., & Cusi, K. J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab417 · Cited by 17
Self-citationCurrent and Emerging Approaches for Hepatic Fibrosis Treatment
Li, J., & Tuo, B. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/6612892 · Cited by 23
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 18
Tang, J., Ma, S., Gao, Y., Zeng, F., Feng, Y., Guo, C., Hu, L., Yang, L., Chen, Y., Zhang, Q., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927763 · Cited by 17
Soresi, M., & Giannitrapani, L. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i30.3541 · Cited by 20
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 20
Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs
Mukherjee, A. G., Wanjari, U. R., Gopalakrishnan, A. V., Katturajan, R., Kannampuzha, S., Murali, R., Namachivayam, A., Ganesan, R., Renu, K., Dey, A., et al. (2022) · Cells · doi:10.3390/cells11243959 · Cited by 17
“The weight gain observed in TZD-treated NAFLD patients is consistent with an enhanced formation of adipose tissue [67].”
BackgroundCardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease
Ren, Z., Wesselius, A., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.002 · Cited by 17
Large-scale metabolomic profiling and incident non-alcoholic fatty liver disease
Gagnon, É., Manikpurage, H. D., Mitchell, P. L., Girard, A. S., Gobeil, É., Bourgault, J., Bégin, F., Marette, A., Thériault, S., & Arsenault, B. J. (2023) · iScience · doi:10.1016/j.isci.2023.107127 · Cited by 16
Bril, F., & Elbert, A. E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156066 · Cited by 17
Self-citationDrug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 19
“Pioglitazone has demonstrated significant therapeutic benefits in patients with MASH, with 58% achieving the primary outcome and 51% experiencing MASH resolution [82].”
Nonalcoholic fatty liver disease: implications for cardiovascular risk
Dinani, A. M., & Sanyal, A. J. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000126 · Cited by 17
Qu, H., Zheng, Y., Wang, Y., Zhang, R., Ruan, X. Z., Yang, G., Liu, Z., & Zheng, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-16074-1 · Cited by 16
Personalized Management of Type 2 Diabetes
Peter, P. R., & Lupsa, B. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1244-0 · Cited by 17
Sumida, Y., Yoneda, M., Toyoda, H., Yasuda, S., Tada, T., Hayashi, H., Nishigaki, Y., Suzuki, Y., Naiki, T., Morishita, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144939 · Cited by 16
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Obesity · doi:10.1002/oby.23250 · Cited by 20
Self-citationRichardson, B., Khan, M. Q., Brown, S. A., Watt, K. D. S., & Izzy, M. J. (2021) · Hepatology Communications · doi:10.1002/hep4.1876 · Cited by 19
Ding, C., Tang, Y., Zhu, W., Huang, P., Lian, P., Ran, J., & Huang, X. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01830-7 · Cited by 16
Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs
Tardelli, M., Claudel, T., Bruschi, F. V., & Trauner, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061777 · Cited by 16
Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum
Tavaglione, F., Targher, G., Valenti, L. V. C., & Romeo, S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.179 · Cited by 16
Yoneda, M., Kobayashi, T., Nogami, A., Iwaki, M., Saito, S., & Nakajima, A. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-579 · Cited by 18
Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier
Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J. S., Mishra, T., Bharadwaj, H. R., Dahiya, D. S., & Jain, V. (2025) · Biomedicines · doi:10.3390/biomedicines13092079 · Cited by 23
“Weight gain was a notable side effect compared to the placebo [57].”
Cardiovascular disease leads to a new algorithm for diabetes treatment
Rodriguez, V., Weiss, M. C., WEINTRAUB, H. S., Goldberg, I. J., & Schwartzbard, A. Z. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.004 · Cited by 16
NAFLD and NASH: The Metabolically Diseased Liver
Armandi, A., & Schattenberg, J. M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_561 · Cited by 18
Camacho, R. C., Polidori, D., Chen, T., Chen, B., Hsu, H. H., Gao, B., Marella, M., Lubomirski, M. S., Beavers, T., Cabrera, J., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14955 · Cited by 35
Yang, Z., Tian, R., Zhang, X., Cai, J., She, Z., & Li, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1120085 · Cited by 26
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
Bali, A. D., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000537 · Cited by 18
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Yilmaz, Y. N., Zeybel, M., Adalı, G., COŞAR, A. M., Sertesen, E., Gökcan, H., Bahçecıoğlu, H., Şahin, M., Kaya, C. T., Ergün, İ., et al. (2023) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0011 · Cited by 21
Altered lipid metabolism and the development of metabolic-associated fatty liver disease
Foster, C., Gagnon, C. A., & Ashraf, A. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000933 · Cited by 19
Khanmohammadi, S., Habibzadeh, A., Kamrul-Hasan, A. B. M., Schuermans, A., & Kuchay, M. S. (2024) · Diabetic Medicine · doi:10.1111/dme.15437 · Cited by 17
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
Nhu, Q., Hsieh, L.-C. Y., Dohil, L., Dohil, R., Newbury, R. O., Kurten, R., Moawad, F., & Aceves, S. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000164 · Cited by 14
“However, recent placebo-controlled long-term studies evaluating pioglitazone for NASH reported that the drug was well tolerated, without major drug-related adverse events (35,38).”
BackgroundKuchay, M. S., Choudhary, N. S., Mishra, S. K., & Misra, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.015 · Cited by 18
Metabolic Associated Fatty Liver Disease in Children—From Atomistic to Holistic
Mărginean, C. O., Meliţ, L. E., & Săsăran, M. O. (2021) · Biomedicines · doi:10.3390/biomedicines9121866 · Cited by 18
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
Self-citationMiglitol attenuates non‐alcoholic steatohepatitis in diabetic patients
Komatsu, M., Tanaka, N., Kimura, T., Fujimori, N., Sano, K., Horiuchi, A., Sugiura, A., Yamazaki, T., Shibata, S., Joshita, S., et al. (2018) · Hepatology Research · doi:10.1111/hepr.13223 · Cited by 15
Shah, R. A., Alkhouri, N., & Kowdley, K. V. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1796968 · Cited by 15
Therapeutic approaches for non-alcoholic steatohepatitis
Gaal, L. F. V., Mertens, J., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211034300 · Cited by 16
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus
Cusi, K. J. (2017) · Gut · doi:10.1136/gutjnl-2017-313958 · Cited by 15
Self-citationPafili, K., Maltezos, E. S., & Παπάνας, Ν. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1413346 · Cited by 15
Grobbee, E. J., de Jong, V., Schrieks, I. C., Tushuizen, M. E., Holleboom, A. G., Tardif, J., Lincoff, A. M., Schwartz, G. G., Cabezas, M. C., & Grobbee, D. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277706 · Cited by 14
“These studies showed favourable effects on NASH and even on liver fibrosis [11,12,24].”
RetractedPsoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
Torosian, K., Lal, E., Kavanaugh, A., Loomba, R. S., Ajmera, V. H., & Gumá, M. (2023) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2023.152165 · Cited by 17
Thipsawat, S. (2023) · SAGE Open Nursing · doi:10.1177/23779608231175581 · Cited by 22
“In addition, the safety of pioglitazone has been studied and found that long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and nonalcoholic steatohepatitis (Cusi et al., 2016).”
BackgroundWang, Y., He, Y., Sun, W., Yu, H., Tao, W., Yu, X., Jia, D., Liu, Y., Pandol, S. J., & Li, L. (2024) · Drugs · doi:10.1007/s40265-024-02015-6 · Cited by 18
Liu, Y., Fan, Y., Liu, J., Liu, X., Li, X., & Hu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1499602 · Cited by 23
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Self-citationMonem, M. S. A., Adel, A., Abbassi, M., Abdelaziz, D. H., Hassany, M., Raziky, M. E., & Sabry, N. A. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102543 · Cited by 16
Ahn, H. Y., Kim, H. H., Hwang, J.-Y., Park, C., Cho, B. Y., & Park, Y. J. (2018) · PPAR Research · doi:10.1155/2018/9568269 · Cited by 14
“Among these drugs, pioglitazone was shown to improve NAFLD in some human studies [5, 6].”
Le, P. N. B., Chaitoff, A. M., Rothberg, M. B., McCullough, A. J., & Alkhouri, N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1704731 · Cited by 15
“Long-term data confirmed these findings [7], and meta-analysis demonstrated that pioglitazone improved advanced fibrosis, fibrosis of any stage, and could”
ResultAmpuero, J., Gallego‐Durán, R., Maya‐Miles, D., Montero, R., Gato, S., Rojas, Á., Gil‐Gómez, A., Múñoz‐Hernández, R., & Romero‐Gómez, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01860-0 · Cited by 17
How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease
Ismaiel, A., & Dumitrascu, D. L. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001174 · Cited by 16
Cusi, K. J., & Leiva, E. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000717 · Cited by 14
Self-citationTargeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 17
Fu, J., Wanxia, X., Gao, X., Xu, J., Wenjuan, Y., Jianrong, L., He, Q., Ma, K., Lian, J., Taixiong, C., et al. (2023) · Journal of Diabetes Research · doi:10.1155/2023/2044090 · Cited by 14
“In addition, pioglitazone can also improve liver histological performance in patients, but there is an unfavorable risk of weight gain, which limits its clinical use, and metformin can improve liver enzyme levels and reduce weight in patients with NAFLD [13, 14].”
BackgroundSun, Y.-D., Zhang, H., Li, Y., & Han, J. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189086 · Cited by 14
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14
Jeong, J. Y., Sohn, J. H., Baek, Y. H., Cho, Y. K., Kim, Y., & Kim, H. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i32.5977 · Cited by 13
Bae, J., Huh, J. H., Lee, M., Lee, Y., & Lee, B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14259 · Cited by 13
Tontikidou, C., Makri, E. S., Evripidou, K., Goulis, D. G., Goulas, A., & Pοlyzos, S. A. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15926 · Cited by 17
Hunter, H., de Gracia Hahn, D., Duret, A., Im, Y. R., Cheah, Q., Dong, J., Fairey, M., Hjalmarsson, C., Li, A., Lim, H. K., et al. (2020) · eLife · doi:10.7554/elife.56573 · Cited by 12
Gellrich, L., & Merk, D. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101310 · Cited by 15
“Although the study aimed at evaluating the efficacy of pioglitazone treatment in patients with NASH and diabetes, a subgroup analysis of the population which is actually suffering from diabetes and NASH is missing [216].”
BackgroundInfluentialTargeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 13
Licata, A., Russo, G. T., Giandalia, A., Cammilleri, M., Asero, C., & Cacciola, I. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030558 · Cited by 14
Chianelli, M., Armellini, M., Carpentieri, M. S., Coccaro, C., Cuttica, C. M., Fusco, A., Marucci, S., Nelva, A., Nizzoli, M., Ponziani, M. C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303282327240507184902 · Cited by 15
Júnior, W. S. D. S., Sposito, A. C., & Godoy‐Matos, A. F. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.034 · Cited by 12
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Metabolic-associated steatotic liver disease and hepatocellular carcinoma
Catalano, G., Chatzipanagiotou, O. P., Kawashima, J., & Pawlik, T. M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2426680 · Cited by 14
“Pioglitazone has been reported to improve fibrosis and steatosis, although it carries the risk of weight gain, heart failure and bone loss [48].”
Zhang, P., Qi, Z., Xu, H., Zhou, L., Zhao, X., Zhong, H., Zhou, W., Fan, B., Wu, H., & Ge, J. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf096 · Cited by 14
The Therapeutic Role of Xenobiotic Nuclear Receptors Against Metabolic Syndrome
Pu, S., Wu, X., Yang, X., Zhang, Y., Dai, Y., Zhang, Y., Wu, X., Liu, Y., Cui, X., Jin, H., et al. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180611083155 · Cited by 13
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.